Note: If you attended the live CE activity AND received CE credit (i.e. a pharmacist CE statement of credit with ACPE UAN 0221-9999-19-284-L01-P), you are NOT allowed to also receive credit for this home-study on-demand web activity.
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
The World Health Organization (WHO) has listed both vaccine hesitancy and a global influenza pandemic as two of the top ten threats in 2019. Overall rates of vaccination in the United States falls far below recommended levels, with only about 43% of adults receiving a yearly influenza vaccine. Fortunately, there is evidence that utilizing pharmacists as immunizers has had a positive effect on immunization rates, increasing access to immunization for the general public. However, given the poor vaccination rates among US adults, there is still a great deal of work to be done by pharmacists and other healthcare professionals in improving vaccine uptake.
This activity will provide pharmacists with education on the burden of influenza, expert guideline updates for treatment in high-risk populations and timing of antiviral initiation, vaccine administration for the prevention of influenza, available therapies, and approaches pharmacists can take to increase uptake of vaccine prophylaxis. Interactive questions will serve to demonstrate and reinforce the latest influenza developments and how to overcome common challenges to adherence or vaccine hesitancy.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
- Discuss risks and complications associated with abstaining from influenza vaccination.
- Demonstrate understanding of updated influenza guidelines from the Infectious Diseases Society of America(IDSA).
- Apply strategies for overcoming vaccine hesitancy.
- Compare and contrast treatments for patients diagnosed with influenza including patient selection criteria, side effect profiles, and monitoring parameters.
Mary S. Hayney, PharmD, MPH
Professor of Pharmacy (CHS)
University of Wisconsin School of Pharmacy
Release Date: August 27, 2019
Expiration Date: September 17, 2020
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-284-H01-P has been assigned to this home study knowledge-based activity (initial release date 8-27-2019). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Hayney has no relevant commercial or financial relationships to disclose.
This activity is supported by an educational grant from Genentech, Inc.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.